Pump's daily trading recs, emphasis on short selling Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Pump's daily trading recs, emphasis on short selling

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Michail Shadkin who wrote (2900)	6/26/2001 2:09:38 PM
From: Bocor	Read Replies (2) of 6873

Michail, any thoughts on XOMA? Secondary done last night I guess. Found this info from a recent article: If Xanelim doesn't get a large chunk of the psoriasis market, then Genentech will still prosper on its diverse portfolio of cancer and heart drugs. But prospects for Genentech's collaborator on Xanelim -- Xoma -- depend greatly on the psoriasis drug. The Berkeley, California, firm would get 25% of profits from Xanelim sales. Those profits would be a first for Xoma which, despite 20 years in the biotech business, has never had a successful product. With Xoma shares sulking down at around 3 last year, several Wall Street analysts became bullish on hopes for Xanelim (and perhaps on hopes for underwriting fees from the cash-poor Xoma). Last week's $13 share price puts a stock market value of $850 million on Xoma and seems to give generous credit to best-case hopes of Xanelim finally pushing Xoma into the black, in 2004. Such speculations were more interesting when the stock was at 3.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next